Novo Nordisk shares rise as Hims abandons $49 weight-loss pill

Core Viewpoint - Novo Nordisk's shares listed in Frankfurt experienced a 4.5% increase following Hims & Hers' decision to reverse the launch of a $49 compounded weight-loss pill due to legal threats from Novo Nordisk [1] Company Summary - Novo Nordisk's stock performance improved significantly, indicating positive market sentiment towards the company after the news regarding Hims & Hers [1] Industry Summary - The telehealth sector, represented by Hims & Hers, faced legal challenges that impacted its product offerings, highlighting the regulatory risks within the weight-loss medication market [1]